Advancing Precision Medicine in Breast Cancer: Applying New Techniques and Approaches to Detect ESR1 Mutations and More

The clinical relevance of ESR1 mutations and review of data supporting serial ctDNA monitoring to detect the emergence of ESR1 mutations (eg, from PADA-1). The comparison of different testing methods for ESR1 mutations and their benefits/drawbacks.

• Appreciate the science and clinical applications of using ESR1 mutations as the dynamic biomarker to manage patients with metastatic breast cancer
• Review data supporting ctDNA-mediated serial ESR1m monitoring, thereby identifying molecular progression before radiological progression of the disease, leading to a change in disease management
• Discuss current and upcoming technologies for testing molecular biomarkers in metastatic breast cancer, including ESR1 mutations